Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results
08 août 2018 07h00 HE
|
Trillium Therapeutics Inc.
Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief Medical OfficerNegotiated...
Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement
19 juin 2018 18h30 HE
|
Trillium Therapeutics Inc.
TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) (“Trillium” or the “Company”), a clinical stage immuno-oncology company developing innovative therapies...
Trillium Therapeutics Completes Amendment to SIRPaFc License Agreement
15 juin 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47
14 juin 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer
07 juin 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
05 juin 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, June 05, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results
11 mai 2018 07h00 HE
|
Trillium Therapeutics Inc.
Focusing TTI-621 clinical development on T-cell lymphomaTTI-621 received Orphan Drug Designation for the treatment of cutaneous T-cell lymphomaPreclinical data with TTI-622 (SIRPaFc IgG4) presented at...
Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting
18 avr. 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics to Report Preclinical Data on TTI-621 and TTI-622 at the AACR Annual Meeting 2018
12 avr. 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs
10 avr. 2018 07h00 HE
|
Trillium Therapeutics Inc.
Successful broad signal-seeking efforts identify T-cell lymphoma as an indication responsive to TTI-621 therapy.Focusing TTI-621 intravenous trial on separate cutaneous and peripheral T-cell lymphoma...